Efect of bivalent human papillomavirus vaccination on pregnancy outcomes: Long term observational follow-up in the Costa Rica HPV vaccine trial

The BMJ

Volumn 351, Issue , 2015, Pages

  Panagiotou, Orestis A ^a   Befano, Brian L ^b   Gonzalez, Paula ^c,d   Rodríguez, Ana Cecilia ^c   Herrero, Rolando ^d   Schiller, John T ^a   Kreimer, Aimée R ^a   Schifman, Mark ^a   Hildesheim, Allan ^a   Wilcox, Allen J ^e   Wacholder, Sholom ^a   Jiménez, Silvia E ^c   Porras, Carolina ^c   Lowy, Douglas R ^a   Sherman, Mark ^a   Pinto, Ligia A ^f   Kemp, Troy J ^f   Sidawy, Mary K ^g   Quint, Wim ^h   Van Doorn, Leen Jan ^h   Struijk, Linda ^h   Palefsky, Joel M ⁱ   Darragh, Teresa M ⁱ   Stoler, Mark H ^j   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

^c PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^f FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h DDL DIAGNOSTIC LABORATORY   (Netherlands)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADULT; ARTICLE; CONTROLLED STUDY; COSTA RICA; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; LIVE BIRTH; MATERNAL AGE; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPONTANEOUS ABORTION; YOUNG ADULT; ABORTION, SPONTANEOUS; ADOLESCENT; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; COSTA RICA; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; MATERNAL AGE; PAPILLOMAVIRUS VACCINES; PREGNANCY; PREGNANCY OUTCOME; YOUNG ADULT;

EID: 84943771585     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h4358     Document Type: Article

References (45)

1. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626-9.
2. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:1-30.
3. Kuehn BM. Immunization recommendations expanded for hepatitis B, HPV, pertussis vaccines. JAMA 2012;307:1353-4.
4. Noronha AS, Markowitz LE, Dunne EF. Systematic review of human papillomavirus vaccine coadministration. Vaccine 2014;32:2670-4.
5. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30(Suppl 5):F123-38.
6. Maglione MA, Gidengil C, Das L, et al. Safety of vaccines used for routine immunization in the United States. Evidence report/technology assessment No 215. Agency for Healthcare Research and Quality, 2014.
7. Institute of Medicine, Committee to Review Adverse Efects of Vaccines. In: Stratton K, Ford A, Rusch E, et al, eds. Adverse efects of vaccines: evidence and causality. IOM, 2011.
8. Global Advisory Committee on Vaccine Safety. 11-12 December 2013. Wkly Epidemiol Rec 2014;89:53-60.
9. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010;340:c712.
10. Westra TA, Rozenbaum MH, Rogoza RM, et al. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-efectiveness analyses. J Infect Dis 2011;204:377-84.
11. Canfell K. Monitoring HPV vaccination programmes. BMJ 2010;340:c1666.
12. Schuchat A. HPV "coverage." N Engl J Med 2015;372:775-6.
13. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008;26:4795-808.
14. Hildesheim A, Wacholder S, Catteau G, et al. Efficacy of the HPV-16/18 vaccine: fnal according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014;32:5087-97.
15. Gonzalez P, Hildesheim A, Herrero R, et al. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Vaccine 2015;33:2141-51.
16. Barfeld WD, Committee on Fetus and Newborn. Standard terminology for fetal, infant, and perinatal deaths. Pediatrics 2011;128:177-81.
17. National Center for Health Statistics (US). State defnitions and reporting requirements for live births, fetal deaths, and induced termination of pregnancy. 1997 revised ed. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, 1997.
18. Moro PL, Museru OI, Niu M, et al. Reports to the Vaccine Adverse Event Reporting System afer hepatitis A and hepatitis AB vaccines in pregnant women. Am J Obstet Gynecol 2014;210:561 e1-6.
19. Irving GJ, Holden J, Yang R, et al. Hepatitis A immunisation in persons not previously exposed to hepatitis A. Cochrane Database Syst Rev 2012;7:CD009051.
20. Maglione MA, Das L, Raaen L, et al. Safety of vaccines used for routine immunization of US children: a systematic review. Pediatrics 2014;134:325-37.
21. Larsen EC, Christiansen OB, Kolte AM, et al. New insights into mechanisms behind miscarriage. BMC Med 2013;11:154.
22. Rai R, Regan L. Recurrent miscarriage. Lancet 2006;368:601-11.
23. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 2006;354:1667-9.
24. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
25. Higgins J P, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
26. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009;5:332-40.
27. Angelo MG, David M P, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014;23:466-79.
28. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
29. Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014;384:2213-27.
30. Clark LR, Myers ER, Huh W, et al. Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health 2013;52:322-9.
31. Goldhaber MK, Fireman BH. The fetal life table revisited: spontaneous abortion rates in three Kaiser Permanente cohorts. Epidemiology 1991;2:33-9.
32. Tavares F, Cheuvart B, Heineman T, et al. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine. Vaccine 2013;31:1759-64.
33. Angelo MG, Zima J, Tavares Da Silva F, et al. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014;23:456-65.
34. Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989;299:541-5.
35. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015;16:775-86.
36. Lucke JF. A critique of the false-positive report probability. Genet Epidemiol 2009;33:145-50.
37. Doshi P, Jeferson T, Del Mar. C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med 2012;9:e1001201.
38. Kmietowicz Z. Clinical study reports are not commercially confdential, says UK government. BMJ 2013;347:f6942.
39. Krumholz HM, Peterson ED. Open access to clinical trials data. JAMA 2014;312:1002-3.
40. Christakis DA, Zimmerman FJ. Rethinking reanalysis. JAMA 2013;310:2499-500.
41. Eichler HG, Abadie E, Breckenridge A, et al. Open clinical trial data for all? A view from regulators. PLoS Med 2012;9:e1001202.
42. Hudson KL, Collins FS. Sharing and reporting the results of clinical trials. JAMA 2015;313:355-6.
43. Institute of Medicine. Sharing clinical trial data: maximizing benefts, minimizing risk. IOM, 2015.
44. Ferris D, Samakoses R, Block SL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics 2014;134:e657-65.
45. Lathyris D, Panagiotou OA, Baltogianni M, et al. Safety of medical interventions in children versus adults. Pediatrics 2014;133:e666-73.